血管生成在胶质母细胞瘤中扮演着重要角色，但大多数抗血管生成治疗试验未能改变本病的不良预后。尽管如此，鉴于贝伐单抗已知可以缓解症状，该药仍在日常实践中使用。我们旨在评估应用贝伐单抗治疗复发性胶质母细胞瘤患者的整体生存率、治疗失败时间、客观反应和临床效益等实际效益。这是一项单中心、回顾性研究，包括了我们机构在2006年至2016年期间治疗的患者。共纳入了202位患者，贝伐单抗治疗的中位持续时间为6个月。治疗失败时间的中位数为6.8个月（95%CI 5.3-8.2），总生存期的中位数为23.7个月（95%CI 20.6-26.8）。50%的患者在第一次MRI评估时出现了放射学反应，56%的患者体验到了症状改善。Ⅰ/Ⅱ级高血压（n=34，17%）和Ⅰ级蛋白尿（n=20，10%）是最常见的副作用。该研究报告了在应用贝伐单抗治疗复发性胶质母细胞瘤患者中的临床效益和可接受的毒副作用剖面。鉴于目前这些肿瘤的治疗方案仍非常有限，该研究支持将贝伐单抗作为治疗选项之一。© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

Angiogenesis plays a key role in glioblastoma, but most anti-angiogenic therapy trials have failed to change the poor outcome of this disease. Despite this, and because bevacizumab is known to alleviate symptoms, it is used in daily practice. We aimed to assess the real-life benefit in terms of overall survival, time to treatment failure, objective response, and clinical benefit in patients with recurrent glioblastoma treated with bevacizumab.This was a monocentric, retrospective study including patients treated between 2006 and 2016 in our institution.202 patients were included. The median duration of bevacizumab treatment was 6 months. Median time to treatment failure was 6.8 months (95%CI 5.3-8.2) and median overall survival was 23.7 months (95%CI 20.6-26.8). Fifty percent of patients had a radiological response at first MRI evaluation, and 56% experienced symptom amelioration. Grade 1/2 hypertension (n = 34, 17%) and grade one proteinuria (n = 20, 10%) were the most common side effects.This study reports a clinical benefit and an acceptable toxicity profile in patients with recurrent glioblastoma treated with bevacizumab. As the panel of therapies is still very limited for these tumors, this work supports the use of bevacizumab as a therapeutic option.© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.